Histogenics Corporation
Histogenics was acquired by Ocugen,(Nasdaq: OCGN) on September 27, 2019. Histogenics (Nasdaq: HSGX) is a leader in personalized restorative cell therapies (RCT) for active living. Our first investigational product candidate, NeoCart® is a proprietary RCT that rebuilds a patient’s own knee cartilage, treating pain at the source and potentially preventing progression to osteoarthritis (OA). Read our community guidelines: https://goo.gl/Qtusgh
7-day free trial · no credit card
Verified contacts
10
available on Kipplo
LinkedIn employees
10
51 to 200 range
Open roles
—
no listings
Distinct roles
10
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 10 verified contacts at Histogenics Corporation
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
10 contacts with verified email or phone · masked until revealed.
- AE
Amnon Eylath
VP Quality Operations · Operations
EmailPhone - MF
Maria Fragoso
HR Manager · Human Resources
EmailPhone - KH
Karla Hix
Clinical Research Coordinator · Healthcare & Human Services
EmailPhone - NT
Neil Thompson
Assistant Materials Scientist · Science
EmailPhone - JS
Jennifer Spiegel
Medical Student at the University of Massachusetts · Other
EmailPhone
Showing 5 of 10 verified contacts
Top roles at Histogenics Corporation
10 distinct titles indexed · top 10 shown.
- 1assistant materials scientist
- 1cfo
- 1clinical research coordinator
- 1director
- 1hr manager
- 1manufacturing associate
- 1medical student at the university of massachusetts
- 1sr director facilities and engineering
- 1validation consultant
- 1vp quality operations
Sign up to unlock all 10 contacts at Histogenics Corporation
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 10 verified contacts at Histogenics Corporation
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.